These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23733559)

  • 1. Comparison of the prevalence of convulsions associated with the use of cefepime and meropenem.
    Tanaka A; Takechi K; Watanabe S; Tanaka M; Suemaru K; Araki H
    Int J Clin Pharm; 2013 Oct; 35(5):683-7. PubMed ID: 23733559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Convulsive liability of cefepime and meropenem in normal and corneal kindled mice.
    Tanaka A; Takechi K; Watanabe S; Tanaka M; Suemaru K; Araki H
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4380-3. PubMed ID: 24841261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study.
    Descombes E; Martins F; Hemett OM; Erard V; Chuard C
    BMC Pharmacol Toxicol; 2016 Feb; 17():4. PubMed ID: 26846675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous epileptiform discharges in patients treated with cefepime or meropenem.
    Naeije G; Lorent S; Vincent JL; Legros B
    Arch Neurol; 2011 Oct; 68(10):1303-7. PubMed ID: 21987544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
    Goff DA; Nicolau DP
    Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy and safety of cefepime in the treatment of bronchopulmonary disease exacerbation in pediatric patients with mucoviscidosis].
    Semykin SIu; Postnikov SS; Polikarpova SV; Dubovik LG; Kolbatova ES
    Antibiot Khimioter; 2005; 50(4):18-22. PubMed ID: 16392335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
    Nakane T; Tamura K; Hino M; Tamaki T; Yoshida I; Fukushima T; Tatsumi Y; Nakagawa Y; Hatanaka K; Takahashi T; Akiyama N; Tanimoto M; Ohyashiki K; Urabe A; Masaoka T; Kanamaru A;
    J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
    Fernandez J; Hilliard JJ; Abbanat D; Zhang W; Melton JL; Santoro CM; Flamm RK; Bush K
    Antimicrob Agents Chemother; 2010 Jan; 54(1):116-25. PubMed ID: 19884364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-Fluorouracil exacerbates cefepime-induced convulsions in pentylenetetrazol-kindled mice.
    Suemaru K; Yoshikawa M; Aso H; Watanabe M
    Epilepsy Res; 2019 Nov; 157():106195. PubMed ID: 31493671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective Comparison of Acute Kidney Injury During Treatment With the Combination of Piperacillin-Tazobactam and Vancomycin Versus the Combination of Cefepime or Meropenem and Vancomycin.
    Peyko V; Smalley S; Cohen H
    J Pharm Pract; 2017 Apr; 30(2):209-213. PubMed ID: 26912532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
    Deal EN; Micek ST; Reichley RM; Ritchie DJ
    Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
    Ong CT; Tessier PR; Li C; Nightingale CH; Nicolau DP
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
    Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The neurotoxicity and safety of treatment with cefepime in patients with renal failure.
    Sonck J; Laureys G; Verbeelen D
    Nephrol Dial Transplant; 2008 Mar; 23(3):966-70. PubMed ID: 18175786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study.
    Su TY; Ye JJ; Yang CC; Huang CT; Chia JH; Lee MH
    Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):52. PubMed ID: 28738848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y; Kobayashi Y
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal cefepime and meropenem dosing for ventilator-associated pneumonia patients with reduced renal function: an update to our clinical pathway.
    Kuti JL; Nicolau DP
    J Crit Care; 2010 Mar; 25(1):155-6. PubMed ID: 20189057
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical and electroencephalographic assessment of cefepime during treatment of nosocomial infections in neurological patients.
    Alvarez SD; Aragon Mdel C; Moreno A; Palomares-Alonso F; Cook HJ; Cardenas G; Soto-Hernandez JL
    Cent Nerv Syst Agents Med Chem; 2011 Sep; 11(3):223-7. PubMed ID: 21919869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefepime-induced neurotoxicity: a systematic review.
    Payne LE; Gagnon DJ; Riker RR; Seder DB; Glisic EK; Morris JG; Fraser GL
    Crit Care; 2017 Nov; 21(1):276. PubMed ID: 29137682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in the use of broad-spectrum antibiotics after cefepime shortage: a time series analysis.
    Plüss-Suard C; Pannatier A; Ruffieux C; Kronenberg A; Mühlemann K; Zanetti G
    Antimicrob Agents Chemother; 2012 Feb; 56(2):989-94. PubMed ID: 22123703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.